Description

PHARMACEUTICAL MARKET RESEARCH PROGRAM

Colchicine in Egypt: A Forgotten Generic at Three Crossroads
Niche Category Analysis: Gout, Familial Mediterranean Fever, and Cardiovascular Repositioning
Data: Audited market sales, Egypt — MAT 2021–2025 · Product & corporation rankings MAT Dec 2025
Opportunity score: 58 / 100

Abstract
Colchicine is one of the oldest anti-inflammatory drugs in continuous clinical use, a molecule derived from the autumn crocus with no patent protection anywhere in the world and no meaningful branded exclusivity in Egypt. The class is small in absolute value — the Egyptian colchicine market is estimated at approximately EGP 118 million on a Moving Annual Total (MAT) basis to December 2025, up from around EGP 65 million in 2021, a four-year value CAGR of roughly 16 percent. Unlike most Egyptian therapeutic classes, its growth is largely real: unit demand has expanded steadily as gout prevalence rises in step with metabolic syndrome, and as three distinct clinical crossroads converge on the same generic molecule. The first crossroad is gout: still the dominant indication, still growing quietly with population and diet. The second is Familial Mediterranean Fever (FMF), a recessively inherited autoinflammatory disease with elevated prevalence in populations of Eastern Mediterranean origin — including a documented Egyptian patient pool — for which colchicine remains the only proven prophylactic therapy. The third is cardiovascular repositioning: the LoDoCo2 (NEJM 2020) and COLCOT (NEJM 2019) trials established low-dose colchicine as an evidence-based anti-inflammatory adjunct in chronic coronary disease and post-myocardial-infarction settings, opening a small but expanding new indication share. This report quantifies the class, maps its brand landscape, decomposes prescriber and indication share, situates the findings against peer-reviewed clinical evidence, and translates the analysis into a strategic reading for local challengers considering entry, positioning, or line extension. We assign an opportunity score of 58 out of 100: modest scale and margin structure, offset by genuine real-terms growth, distinctive MENA-specific epidemiology, and a novel indication trajectory that no market-intelligence house has yet quantified for this market.